Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New biotech business model will 'address pharma's research outsourcing trend'

This article was originally published in Scrip

Executive Summary

The German biotech company 4SC has decided to transfer most of its early-stage research activities to a 100%-owned subsidiary. "We are convinced this new business model addresses the current trends in the pharma industry to collaborate more in early stage R&D," Dr Ulrich Dauer, CEO of 4SC, told Scrip.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015562

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel